Management Presentation: Biosimilar Pipeline and Margin Improvement Strategy
Segment to Carve-out sales, business and geographical breakdown
In USD bn
Segment sales
FY 2020
FY 2021
FY 2022
H1 2022
H1 2023
9.6
9.6
9.2
4.6
4.8
Adjustments¹
-0.1
-0.2
-0.2
0.0
0.0
Carve-out sales
9.5
9.4
9.1
4.6
4.8
vs PY (in USD)
-0%
-4%
5%
vs PY (in cc²)
-2%
4%
8%
Carve-out sales
9.5
9.4
9.1
4.6
4.8
Generics
7.7
7.5
7.1
3.6
3.7
Biosimilars
1.8
1.9
1.9
0.9
1.0
Carve-out sales
9.5
9.4
9.1
4.6
4.8
Europe
4.7
4.8
4.5
2.3
2.5
North America
2.5
International
2.3
2.2
2.5
2.1
1.0
1.0
2.5
1.2
1.2
Note: Based on Sandoz division's reporting and carve-out financials. Numbers may not add up due to rounding. 1. Reflect mainly the transfers of the Sandoz Division's biotechnology manufacturing services to other companies' activities and the Coartem
brand to the Innovative Medicines Division; 2. Constant currencies
34
Management Presentation
SANDOZView entire presentation